



2nd POSTGRADUATE

Lymphoma
Conference

Rome,
March 17-18
2016

VOI Donna Camilla Savelli Hotel

Presidents:

A.M. Carella
P.L. Zinzani

Scientific Committee:

A.M. Carella
B.D. Cheson
S.A. Pileri
A. Younes
P.L. Zinzani

Rome, March 17-18 2016

Faculty

Stephen M.	Ansell	Rochester, USA
Philippe	Armand	Boston, USA
Sally F.	Barrington	London, United Kingdom
Angelo Michele	Carella	Genova, Italy
Bruce D.	Cheson	Washington, USA
Francesco	D'Amore	Aarhus, Denmark
Jonathan	Friedberg	Rochester, USA
Tim	Illidge	Manchester, United Kingdom
Steven M.	Horwitz	New York, USA
Youn H.	Kim	Stanford, USA
Ralf	Küppers	Essen, Germany
Ari M.	Melnick	New York, USA
Craig H.	Moskowitz	New York, USA
Owen A.	O'Connor	New York, USA
Stefano	Pileri	Milano, Italy
Barbara	Pro	Chicago, USA
Stephen	Schuster	Philadelphia, USA
Anna	Sureda	Cambridge, United Kingdom
Ralf U.	Trappe	Berlin, Germany
Hans-Guido	Wendel	New York, USA
Wyndham H.	Wilson	Bethesda, USA
Anas	Younes	New York, USA
Pier Luigi	Zinzani	Bologna, Italy

Thursday, March 17, 2016

8.30 am Welcome and Introduction
A.M. Carella, P.L. Zinzani

Session I

Hodgkin Lymphoma

Chairmen: A.M. Carella, P.L. Zinzani

8.45 am	Pathobiology <i>R. Küppers</i>
9.00 am	General discussion
9.15 am	The "PET world" <i>S.F. Barrington</i>
9.30 am	General discussion
9.45 am	Salvage treatment with Brentuximab Vedotin as a single agent and in combination with Bendamustine <i>C.H. Moskowitz</i>
10.00 am	General discussion
10.15 am	News on Autotransplant <i>A. Sureda</i>
10.30 am	General discussion
10.45 am	Update on the role of anti-PD1 and anti-PD-L1 <i>S.M. Ansell</i>
11.00 am	General discussion
11.15 am	Coffee break
11.30 am	The advent of new "chemofree" therapy <i>A. Younes</i>
11.45 am	General discussion

Hodgkin
Hodgkin

12.00 pm	News on allogeneic transplantation: <ul style="list-style-type: none"> • BV after Allo <i>T. Illidge</i> • Anti-PD1 after allo <i>S.M. Ansell</i> • Allo post Anti-PD1 <i>P. Armand</i>
12.45 pm	General discussion
1.00 pm	Other “newer” potential agents <i>A. Younes</i>
1.15 pm	General discussion
1.30 pm	Lunch

Session II

T-cell lymphoma

Chairmen: *S.A. Pileri, P.L. Zinzani*

2.30 pm	CD30 expression: a real peculiar enigma? <i>S.A. Pileri</i>
2.45 pm	General discussion
3.00 pm	Different front-line treatments related to the histologic subtypes in PTCL: is it possible today? <i>S.M. Horwitz</i>
3.15 pm	General discussion
3.30 pm	A focus on new agents for PTCL <i>O. O'Connor</i>
3.45 pm	General discussion
4.00 pm	Should ASCT in 1st remission be the standard of care for patients with PTCL? <i>Against B. Pro Pro F. D'Amore</i>
4.30 pm	General discussion
4.45 pm	New agents in: <ul style="list-style-type: none"> • PTCL <i>B. Pro</i> • CTCL <i>Y.H. Kim</i>
5.15 pm	General discussion

Session III

Follicular Lymphoma

Chairmen: *B.D. Cheson, O. O'Connor*

- 8.30 am **Current role of epigenetic changes in follicular lymphoma**
A.M. Melnick
- 8.45 am General discussion
- 9.00 am **Microenvironment modulation as a therapeutic strategy**
H.G. Wendel
- 9.15 am General discussion
- 9.30 am **Novel Targets/Therapies**
- **BTK inhibitors** *B.D. Cheson*
 - **PI3K inhibitors** *A. Younes*
 - **BCL-2 inhibitors** *J. Friedberg*
 - **Proteasome inhibitors** *O. O'Connor*
- 10.30 am General discussion
- 10.45 am **The new concept of chemotherapy-free treatment regimens**
B.D. Cheson
- 11.15 am Coffee break

Follicular

Session IV

Diffuse Large B-Cell Lymphoma

Chairman: *A. Younes*

- 11.30 am **Update on the treatment of "Grey Zone" lymphomas: conventional and innovative therapeutic approaches**
W.H. Wilson
- 11.45 am General discussion
- 12.00 pm **Is there a role for Brentuximab Vedotin in the treatment of DLBCL?**
S.M. Ansell
- 12.15 pm General discussion
- 12.30 pm **Treatment of post-transplant lymphoproliferative disease**
R.U. Trappe
- 12.45 pm General discussion
- 1.00 pm **New advances on CAR T-cells**
S. Shuster
- 1.15 pm General discussion
- 1.30 pm Arrivederci

Diffuse Large B-Cell

With an unrestricted educational grant of:



GENERAL INFORMATION

Meeting Venue

VOI Donna Camilla Savelli Hotel
Via Garibaldi, 27
00153 Rome, Italy
Phone +39 06 588861 - Fax +39 06 5882101
www.hoteldonnacamillasavelli.com

Official Language

English.

Slides

Slides must be in English. Computer videoprojection will be available in Power Point.
Other requirements should be communicated to the Organizing Secretariat as soon as possible.
Slides should be handed to the slide center one hour before the beginning of the session and collected at the end.

Badge

All registered participants and speakers will be given a badge which they must wear to be admitted to the scientific sessions.

Attendance certificate

A certificate will be given to all participants at the end of the meeting.

CME

A request for Italian CME credits have been made as follows:

- Provider Studio ER Congressi SRL: ID 828-146128
- No. 12 CME credits for physicians (disciplines: Hematology, Oncology, Radiotherapy).
- Educational objective: "guidelines-protocols-procedures".

Changes

Parts of the program may be changed without notice.

Organizing Secretariat:

Studio E.R. Congressi
Via Marconi, 36 - 40122 Bologna
Phone +39 051 4210559 - Fax +39 051 4210174
ercongressi@ercongressi.it
www.ercongressi.it